Citalopram in the Treatment of Binge-Eating Disorder: A Placebo-Controlled Trial
J Clin Psychiatry 2003;64:807-813
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Binge-eating disorder is a newly
recognized eating disorder characterized by recurrent episodes of
binge eating without compensatory weight loss behaviors. It
commonly co-occurs with depressive disorders and obesity.
Citalopram is a highly selective serotonin reuptake inhibitor
antidepressant. The purpose of this study was to assess the
efficacy and safety of citalopram in the treatment of
Method: Thirty-eight outpatients with a DSM-IV
diagnosis of binge-eating disorder were enrolled in the study
between August 2000 and July 2001 and were randomly assigned to
receive either citalopram (N = 19) or placebo (N = 19) in a
6-week, double-blind, flexible-dose (20-60 mg/day) study. The
primary measure of efficacy was frequency of binge-eating
episodes. Secondary measures included frequency of binge days,
body mass index (BMI), weight, Clinical Global
Impressions-Severity of Illness scale scores, Yale-Brown
Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE)
scores, Hamilton Rating Scale for Depression (HAM-D) scores, and
response categories. The outcome measures were analyzed using 2
random regression methods, with a time trend analysis (primary
analysis) and an endpoint analysis. In addition, response
categories were analyzed using an exact trend test.
Results: Compared with placebo-treated subjects,
subjects receiving citalopram (mean dose
of 57.9 mg/day) had a significantly greater rate of reduction
in frequency of binge eating (p = .003), frequency of binge days
(p < .001), BMI (p < .001), weight (p < .001), severity
of illness (p = .028), and YBOCS-BE score (p = .007) and a
marginally significant rate of reduction in HAM-D score (p =
.053). Differences between groups in response categories were
marginally significant (p = .068 for intent-to-treat analysis).
Conclusion: In a 6-week, placebo-controlled,
flexible-dose trial, citalopram was efficacious in reducing
binge-eating frequency, weight, and severity of illness and was
generally well tolerated in subjects with binge-eating